Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Receivables (2016 - 2025)

Cytosorbents (CTSO) has disclosed Receivables for 14 consecutive years, with $13.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Receivables rose 16.96% year-over-year to $13.4 million, compared with a TTM value of $13.4 million through Sep 2025, up 16.96%, and an annual FY2024 reading of $11.7 million, up 18.62% over the prior year.
  • Receivables was $13.4 million for Q3 2025 at Cytosorbents, down from $14.4 million in the prior quarter.
  • Across five years, Receivables topped out at $14.4 million in Q2 2025 and bottomed at $7.5 million in Q4 2021.
  • Average Receivables over 5 years is $10.6 million, with a median of $9.9 million recorded in 2023.
  • Peak annual rise in Receivables hit 53.12% in 2021, while the deepest fall reached 7.75% in 2021.
  • Year by year, Receivables stood at $7.5 million in 2021, then increased by 26.09% to $9.5 million in 2022, then rose by 4.38% to $9.9 million in 2023, then increased by 18.62% to $11.7 million in 2024, then grew by 14.28% to $13.4 million in 2025.
  • Business Quant data shows Receivables for CTSO at $13.4 million in Q3 2025, $14.4 million in Q2 2025, and $13.5 million in Q1 2025.